Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

CYTK

Cytokinetics (CYTK)

Cytokinetics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CYTK
DateTimeSourceHeadlineSymbolCompany
13/01/202523:30GlobeNewswire Inc.Cytokinetics Announces 2025 Corporate Milestones and Vision 2030NASDAQ:CYTKCytokinetics Inc
11/01/202508:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
08/01/202508:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
07/01/202508:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
07/01/202508:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
07/01/202508:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
07/01/202508:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
07/01/202508:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
07/01/202508:00GlobeNewswire Inc.Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CYTKCytokinetics Inc
04/01/202508:00GlobeNewswire Inc.Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:CYTKCytokinetics Inc
23/12/202423:30GlobeNewswire Inc.Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyNASDAQ:CYTKCytokinetics Inc
20/12/202416:00GlobeNewswire Inc.Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater ChinaNASDAQ:CYTKCytokinetics Inc
17/12/202411:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
17/12/202408:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTKCytokinetics Inc
17/12/202408:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
13/12/202408:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
11/12/202409:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
11/12/202408:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
06/12/202408:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
06/12/202408:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
06/12/202408:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
06/12/202408:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
06/12/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
04/12/202408:00GlobeNewswire Inc.Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CYTKCytokinetics Inc
03/12/202423:30GlobeNewswire Inc.Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection FractionNASDAQ:CYTKCytokinetics Inc
03/12/202410:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
03/12/202408:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
03/12/202408:00GlobeNewswire Inc.Cytokinetics to Participate in December Investor ConferencesNASDAQ:CYTKCytokinetics Inc
02/12/202423:30GlobeNewswire Inc.Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyNASDAQ:CYTKCytokinetics Inc
27/11/202411:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
 Showing the most relevant articles for your search:NASDAQ:CYTK